이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Sernova 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Cynthia Pussinen

최고 경영자

CA$2.6m

총 보상

CEO 급여 비율	3.6%
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	5.7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Cynthia Pussinen 의 보수는 Sernova 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jul 31 2024	n/a	n/a	-CA$39m
Apr 30 2024	n/a	n/a	-CA$41m
Jan 31 2024	n/a	n/a	-CA$41m
Oct 31 2023	CA$3m	CA$92k	-CA$39m

보상 대 시장: Cynthia 의 총 보상 ($USD 1.88M )은 German 시장( $USD 434.78K ).

보상과 수익: Cynthia 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Cynthia Pussinen

less than a year

테뉴어

CA$2,574,600

보상

Ms. Cynthia Pussinen is Chief Executive Officer & Director at Sernova Corporation from September 2023. She served as an Executive Vice President of Technical Operations and Supply Chain at Actinium Pharmac...

리더십 팀

이름	위치	테뉴어	보상	소유권
Cynthia Pussinen	CEO & Director	less than a year	CA$2.57m	데이터 없음
Modestus Obochi	Chief Business Officer	less than a year	CA$996.01k	0.015% CA$ 8.0k
Frank Shannon	Vice President of Clinical Development & Regulatory Affairs	3.1yrs	CA$463.26k	데이터 없음
Jonathan M. Rigby	Executive Chairman	less than a year	데이터 없음	데이터 없음
Nicholas Rossettos	Interim Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Douglas Maret	Chief Science Officer	no data	데이터 없음	데이터 없음
Christopher Barnes	Vice President of Investor Relations	2.8yrs	CA$352.33k	데이터 없음

1.0yrs

평균 재임 기간

경험이 풍부한 관리: PSH 의 관리팀은 경험 (평균 재직 기간 0.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Cynthia Pussinen	CEO & Director	less than a year	CA$2.57m	데이터 없음
Jonathan M. Rigby	Executive Chairman	less than a year	데이터 없음	데이터 없음
James Parsons	Independent Director	12.4yrs	CA$183.27k	0.12% CA$ 61.2k
Norman C. Wong	Member of Scientific Advisory Board	18.2yrs	데이터 없음	데이터 없음
Jannette Dufour	Member of Scientific Advisory Board	18.1yrs	데이터 없음	데이터 없음
George King	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Clive Patience	Member of Scientific Advisory Board	17.8yrs	데이터 없음	데이터 없음
Steven Paraskevas	Member of Scientific Advisory Board	13.8yrs	데이터 없음	데이터 없음
David Lillicrap	Member of Scientific Advisory Board	5.7yrs	데이터 없음	데이터 없음
Anke Schulte	Member of Global Advisory Board	4.2yrs	데이터 없음	데이터 없음
Stephen Sangha	Independent Director	1.4yrs	CA$158.36k	4% CA$ 2.1m
Sam Wiseman	Member of Scientific Advisory Board	3.4yrs	데이터 없음	데이터 없음

5.7yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: PSH 의 이사회는 경험(평균 재직 기간 5.4 년)으로 간주됩니다.

Sernova 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Independent Director recently sold €149k worth of stock

Less than half of directors are independent

Sernova Corp. Appoints Jonathan Rigby as Executive Chairman

Sernova Corp. Appoints Jonathan Rigby to Board of Directors

Sernova Corp., Annual General Meeting, Apr 30, 2024

Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer

Recent updates

Sernova Corp. Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

Sernova Corp. announced that it has received CAD 5.2 million in funding

Independent Director recently sold €149k worth of stock

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Less than half of directors are independent

Sernova Corp. Appoints Jonathan Rigby as Executive Chairman

Sernova Corp. Appoints Jonathan Rigby to Board of Directors

New major risk - Share price stability

New minor risk - Market cap size

Sernova Corp., Annual General Meeting, Apr 30, 2024

New minor risk - Financial position

New minor risk - Share price stability

Sernova Corp. Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress

Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress

Sernova Corp. Announces New Preclinical Data for its Novel Cell Therapy Platform, Cell Pouch System, as Potential Treatment for Post-Operative Hypothyroidism at 2023 American Thyroid Association Annual Meeting

Sernova Corp. Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device

Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer

Chairman recently bought €162k worth of stock

Sernova Corp Appoints Modestus Obochi as Chief Business Officer

Sernova Corp. Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™? at American Diabetes Association 83rd Scientific Sessions

New major risk - Financial position

Sernova Corp. Announces Executive Changes

Less than half of directors are independent

Sernova Corp., Annual General Meeting, Apr 27, 2023

Sernova Announces Advancements with Its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy

Sernova Corp. Announces Executive Changes

Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of Its US Phase 1/2 Clinical Trial for Type 1 Diabetes

Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes

Sernova Corp. Appoints Daniel Mahony, Ph.D. to Its Board of Directors, Effective from September 30, 2022

Sernova Corp. Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System Tm at American Diabetes Association 82nd Scientific Sessions 2022

Sernova Corp.(TSXV:SVA) dropped from S&P/TSX Venture Composite Index

Sernova Corp. announced that it has received CAD 20.323499 million in funding from Evotec SE

Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation At American Diabetes Association 82Nd Scientific Sessions 2022

No longer forecast to breakeven

Sernova Corp., Annual General Meeting, Apr 28, 2022

Sernova Corp. Announces Publication of A Peer Reviewed Preclinical Study Demonstrating Positive Results of A Novel Cell Pouch System Cell Therapy

Sernova Corp. Provides Progress Update on Its Phase 1/2 T1d Clinical Trial

Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference

Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium

Forecast to breakeven in 2024

Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference

Chief Financial Officer recently bought €51k worth of stock

Sernova Corp. has completed a Composite Units Offering in the amount of CAD 20.04 million.

Sernova Corp Announces Second Annual Data Safety Monitoring Board Review of its Diabetes Cell Pouch System Clinical Trial and Recommendation for Protocol Continuation

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령